Effect of oral estradiol on Lp (a) and other lipoproteins in postmenopausal women: A randomized, double-blind, placebo-controlled, crossover study

Archives of Internal Medicine

Volumn 156, Issue 8, 1996, Pages 866-872

  Haines, Christopher ^a   Chung, Tony ^a   Chang, Allan ^a   Masarei, John ^a   Tomlinson, Brian ^a   Wong, Eric ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; ESTRADIOL; ESTROFEM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESTRADIOL; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPOPROTEIN(A); MIDDLE AGED; POSTMENOPAUSE;

EID: 0029874152     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.8.866     Document Type: Article

References (49)

1. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality preliminary results from the Lipid Research Clinics Program Follow-up Study JAMA. 1983,245:903-906
2. Hjortland MC, McNamara PM, Kannel WB Some atherogenic concomitants of menopause the Framingham study Am J Epidemiol 1976,103 304-311
3. Heiss G, Haskell W, Mowery R, et al Lipoprotein cholesterol distributions in selected North American populations: the Lipid Research Clinics Program prevalence study. Circulation 1980;61:302-315
4. Colditz GA, Willett WC. Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and risk of coronary heart disease in women. N Engl J Med. 1987; 316:1105-1110.
5. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary artery disease: the Framingham Study. Ann Intern Med. 1971;74 1-12.
6. Gordon TL, Castelli WP, Hjortland MC, Kannel WB, Dawber TR High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977,62:707-714.
7. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis and longevity. Circulation. 1966;34:679-697.
8. Stampfer MJ, Sacks FM, Salvini S. Willett WC, Henekens CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction N Engl J Med. 1991;325:378-381
9. Kostner GM, Avogara P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981,38-51-61.
10. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography Circulation 1986;74:758-765
11. Genest J, McNamara JK, Ordovas JM. et al. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992,19:792-802.
12. Woo J, Lau E, Lam CWK, et al. Hypertension, lipoprotein (a), and apolipoprotein A-1 as risk factors for stroke in the Chinese. Stroke. 1991;22:203-208.
13. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986,256:2540-2544
14. Sandkamp M, Assman G. Lipoprotein (a) in PROCAM participants and young myocardial infarction survivors. In. Scanu AM, ed Lipoprotein (a). New York, NY. Academic Press; 1990:205-209.
15. Levitsky LL, Scanu A, Gould SH. Lipoprotein (a) levels in black and white children and adolescents with IDDM. Diabetes Care. 1991;14 283-287.
16. Haffner SM, Tuttle KR, Rainwater DL. Decrease of lipoprotein (a) with improved glycemic control in IDDM subjects Diabetes Care. 1991;14:302-307.
17. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis Clin Chem. 1987;33.721.
18. Miller VT, Muesing RA, LaRosa JC. Stoy DB, Phillips EA. Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein sub-fractions, and apolipoproteins A-1. Obstet Gynecol. 1991;77:235-240
19. Barnes RB, Roy S, Lobo RA Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women Obstet Gynecol. 1985;66:216-219.
20. Ottosson UB, Johansson BG, von Sehoultz B. Subtractions of high-density lipoprotein cholesterol during oestrogen therapy: a comparison between progestins and natural replacement therapy. Am J Obstet Gynecol. 1985;15:746-750.
21. Sonnendecker EWW, Polakow ES, Benade AJ, Simchowitz E. Serum lipoprotein effects of conjugated estrogen and sequential conjugated estrogenmedrogestone regimen in hysterectomized postmenopausal women. Am J Obstet Gynecol. 1989;160:1128-1134.
22. Brewer HB. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels In Scanu AM, ed Lipoprotein (a). New York, NY: Academic Press; 1990 211-220.
23. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989,226.271-276
24. Illingworth DR, Stein EA, Mitchell YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med. 1994,154:1586-1595.
25. Sacks FM, McPherson R, Walsh BW Effect of postmenopausal estrogen replacement on plasma Lp(a) concentrations Arch Intern Med. 1994;154:1106-1110
26. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein-cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-505.
27. Hills M, Armitage P. The two-period cross-over trial. Br J Clin Pharmacol. 1979;8:7-20
28. Owens D, Cox M, Caird J, et al. Altered regulation of cholesterol metabolism in type I diabetic women during the menstrual cycle. Diabet Med. 1993;10:647-653.
29. Zechner R, Desoye G, Schweditsch MO, Pfeiffer KP, Kostner GM. Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum. Metabolism. 1986,35:333-336.
30. Panteghini M, Pagani F. Serum concentrations of lipoprotein (a) during normal pregnancy and postpartum. Clin Chem. 1991;37:2009-2010
31. Seed M, Doherty E, O'Connor B, Reaveley D. Effect of high endogenous oestrogen levels on lipoprotein concentration. J Endocrinol. 1991;131:73.
32. Kuhl H, Marz W, Jung-Hoffman C, Weber J, Siekmeier R, Gross W. Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels. Contraception. 1992;47.69-83
33. Deplanque B, Beaumont V, Lemort N, Beaumont JL. Lp(a) levels and antiestrogen antibodies in women with and without thrombosis in the course of oral contraception. Atherosclerosis. 1993;100:183-188.
34. Albers JJ, Taggart HM, Applebaum-Bowden O, Haffner S, Chestnut CH, Hazzard W Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D, and the Lp(A) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta. 1984;795:293-296.
35. Farish E, Rolton HA, Barnes JF, Hart DM Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ. 1991;303 694.
36. Crook D, Sidhu M, Seed M, O'Donnell M, Stevenson JC Lp(a) levels in women given danazol, an impeded androgen. Atherosclerosis. 1992;92:41-47.
37. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. J Clin Invest 1992;89.1166-1171.
38. Hiraga T, Harada K, Kobayashi T, Murase T. Reduction of serum lipoprotein (a) using estrogen in a man with familial hypercholesterolemia. JAMA 1992; 267:2328.
39. Soma MZ, Osnago-Gadda I, Paoletti R, et al. The lowering of Lp(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993;153:462-1468.
40. Kim CJ, Hak CJ, Dong HC, Yong KM Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women. Arterioscler Thromb Vas Biol. 1994,14.275-281.
41. Soma M, Fumagalli R, Paoletti R, et al. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women. Lancet. 1991;337:612.
42. Van der Mooren MJ, Demacker PNM, Thomas CMG, Rolland R Beneficial effects on serum lipoproteins by 17-oestradiol-hydrogesterone therapy in postmenopausal women, a prospective study. Eur J Obstet Gynecol Reprod Biol. 1992,47:153-160.
43. Marsh MS, Crook D, Whitcroft SIJ, Worthington M, Whitehead M, Stevenson J Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins Obstet Gynecol. 1994;83 19-23.
44. Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Paul WL Lp(a) lipoprotein relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol. 1992,166:1182-1190.
45. Nabulsi AA, Folsom AR, White A, et al Association of hormone-relacement therapy with various cardiovascular risk factors in postmenopausal women N Engl J Med 1993;328:1069-1075
46. Floren CH, Albers JJ, Bierman EL Uptake of Lp(a) lipoprotein by cultured fibrobalasts. Biochem Biophys Res Commun. 1981;102 636-639
47. Martmann-Moe K, Berg K Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor. Clin Genet. 1981,20:352-362.
48. Haines CJ, Chung TKH, Masarei JRL. Tomlinson B, Lau JTF The effect of percutaneous oestrogen replacement therapy on Lp(a) and other lipoproteins. Maturitas. In press.
49. Wren BG. The effect of oestrogen on the female cardiovascular system. Med J Aust 1992,157:204-208.